10x Genomics, Inc. (TXG) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for 10x Genomics, Inc. (TXG): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 42/100 — a percentile rank of 10x Genomics, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $11.6B |
| P / S | 18.8× |
| EV / EBITDA | -213.6× |
| Gross margin | 70.0% |
| Operating margin | -14.3% |
| Net margin | -12.2% |
| Return on equity | -9.1% |
| ROIC | -27.4% |
| Revenue growth | -4.3% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is 10x Genomics, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from 10x Genomics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact